Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Amgen Inc.

Community Practice Connections™: Medical Crossfire®: A New Dawn of T-Cell–Engaging Immunotherapy: Improving Outcomes for Patients with Acute Lymphoblastic Leukemia

Release Date: November 27, 2019
Expiration Date: November 27, 2020
Media: Internet - based

Activity Overview

This activity will feature reviews of the latest data covering advances in treatment for acute lymphoblastic leukemia (ALL), followed by case presentations and expert discussion to place emerging treatment options into context. The emergence of T-cell engaging therapies to treat lymphomas and leukemias have created new opportunities in the treatment of relapsed/refractory ALL or ALL in remission with measurable residual disease (MRD). Bispecific T-cell engagers can redirect T-cells to exert cytotoxic activity against tumor cells and have demonstrated efficacy in B-cell ALL (B-ALL). However, identifying which patients and at which point in therapy these new agents should be used can be challenging given rapidly emerging data and advances in strategies to monitor response to lines of therapy, such as MRD.

Benefits of Participating

At the conclusion of this continuing medical education (CME) activity, you should be better prepared to:

  • Gain an understanding of the latest data regarding the use of T-cell engaging therapies in the treatment of ALL.
  • Hear expert perspective on how and when to apply the latest advances in treatment for ALL.
  • Utilize real-world case studies to challenge your treatment decision-making in light of emerging options and novel data in ALL.
  • Acknowledgement of Commercial Support

    This activity is supported by an educational grant from Amgen Inc.

    Instructions for This Activity and Receiving Credit

    • You will need to log in to participate in the activity.
    • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
    • At the end of the activity, “Educational Content/Videos” will be available for your reference.
    • In order to receive a CME/CE Certificate, you must complete the activity.
    • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.

    Target Audience

    This educational activity is intended for international hematologists, medical oncologists, and other healthcare professionals interested in the latest advances in the treatment of patients with acute lymphoblastic leukemia (ALL). Fellows, investigators, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with ALL are also invited to participate.

    Learning Objectives

    Upon successful completion of this educational activity, you should be better prepared to:

    • Describe the biology of ALL in terms of biomarkers, testing strategies, and methods to stratify risk for patients with this hematologic malignancy.
    • Differentiate the role of T-cell–engaging immunotherapy in measurable residual disease status in treatment decisions for patients with ALL.
    • Incorporate key findings from recent clinical trials concerning the use of T-cell–engaging immunotherapy treatment strategies for patients with ALL in the frontline and relapsed/refractory settings into practice.
    • Discuss recent evidence and clinical trials involving T-cell immunotherapies in other hematological malignancies.

    Faculty, Staff, and Planners’ Disclosures


    Elias Jabbour, MD
    Elias Jabbour, MD
    Professor of Medicine
    Department of Leukemia
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Disclosures:Grant Research Support: AbbVie, Amgen Inc, Bristol-Myers Squibb, Novartis, Pfizer, Takeda; Consultant: AbbVie, Adaptive Biotechnologies, Amgen Inc, Astellas Pharma, Bristol-Myers Squibb, Novartis, Pfizer, Takeda

    Naval G. Daver, MD
    Naval G. Daver, MD
    Associate Professor
    Department of Leukemia
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Disclosures: Grant Research Support: Bristol-Myers Squibb, Pfizer, Incyte Corporation, AbbVie, Daiichi Sankyo, Genentech, Astellas Pharma, Servier, Nohla Therapeutics; Consultant: AbbVie, Novartis, Agios Pharmaceuticals, Incyte Corporation, Pfizer, Astellas Pharma, Jazz Pharma, Bristol-Myers Squibb, Daiichi
    Sankyo, Servier, Celgene.

    Hagop M. Kantarjian, MD
    Hagop M. Kantarjian, MD
    Professor and Chair, Department of Leukemia
    Samsung Distinguished Leukemia Chair in Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Disclosures: Grant Research Support: AbbVie, Agios Pharmaceuticals, Amgen Inc, Astex Pharmaceuticals, Bristol-Myers Squibb, Cyclacel Pharmaceuticals, Daiichi Sankyo, ImmunoGen, Jazz Pharma, Novartis, Pfizer, Takeda; Other: Honoraria: AbbVie, Actinium Pharmaceuticals, Agios Pharmaceuticals, Amgen Inc, ImmunoGen, Pfizer, Takeda.

    Giovanni Martinelli, MD
    Giovanni Martinelli, MD
    Scientific Director
    Scientific Institute of Romagna for the Study and Treatment of Cancer
    Meldola, Italy
    Associate Professor in Hematology
    Department of Hematology and Sciences Oncology
    Institute of Hematology “L. e A. Seràgnoli”
    University of Bologna
    Bologna, Italy

    Disclosures: Giovanni Martinelli, MD, has no relevant financial relationships with commercial interest to disclose.

    The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

    Disclosure Policy and Resolution of Conflicts of Interest (COI)

    As a sponsor accredited by the ACCME, PER® makes it a policy to ensure fair balance, independence, objectivity, and scientific rigor in all its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a COI.

    Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

    Off-Label Disclosure and Disclaimer

    This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

    The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By